Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria.

Saved in:
Bibliographic Details
Title: Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria.
Authors: Won, Chong Hyun1 (AUTHOR), Park, Chun Wook2 (AUTHOR), Ahn, Jiyoung3 (AUTHOR), Ko, Joo Yeon4 (AUTHOR), Cho, Sang Hyun5 (AUTHOR), Lee, Yang Won6 (AUTHOR), Lee, Joo Hee7 (AUTHOR), Ng, Khai Jing7 (AUTHOR), Hong, Min Young7 (AUTHOR), Zhong, Jinglin8 (AUTHOR), Dossenbach, Martin7 (AUTHOR), Son, Sang Wook9 (AUTHOR) skin4u@korea.ac.kr
Source: JEADV Clinical Practice. Jun2026, Vol. 5 Issue 2, p529-537. 9p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:27686566
DOI:10.1002/jvc2.70271